Our previous study showed that afatinib, a clinically available EGFR-TKI for lung cancer therapy, attenuated oxygen-glucose deprivation (OGD)-induced neuroinflammation in primary cultured astrocytes [15]. The gene discussed is EGFR; the disease is lung carcinoma.